Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mauriac

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
La Nouvelle Presse Medicale|June 16, 1979
[The treatment of Cushing's syndrome by selective excision of pituitary adenoma. 3 cases (author's transl)]J Riviere, G Manciet, P Roger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trialP F Conte, P G Giannessi, J Latreille, et al.
Journal of Medical Genetics|May 6, 2008
Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approachF Chibon, C Primois, J-M Bressieux, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 1995
Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancerC T Tyrrell, P F Bruning, F May-Levin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 1999
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)L Mauriac, G MacGrogan, A Avril, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2005
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapyR Arriagada, M G Lê, M Spielmann, et al.
Breast Cancer Research and Treatment|April 26, 2012
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicityM Toulmonde, N Madranges, V Brouste, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1988
Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trialJ Bonneterre, L Mauriac, B Weber, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/dayJ Bonneterre, H Coppens, L Mauriac, et al.
Chirurgie; Memoires De L'Academie De Chirurgie|September 30, 1998
[Results of 10 years of a randomized trial of neoadjuvant chemotherapy in breast cancers larger than 3 cm]A Avril, A Faucher, E Bussières, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
La Nouvelle Presse Medicale|June 16, 1979
[The treatment of Cushing's syndrome by selective excision of pituitary adenoma. 3 cases (author's transl)]J Riviere, G Manciet, P Roger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trialP F Conte, P G Giannessi, J Latreille, et al.
Journal of Medical Genetics|May 6, 2008
Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approachF Chibon, C Primois, J-M Bressieux, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 1995
Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancerC T Tyrrell, P F Bruning, F May-Levin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 1999
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)L Mauriac, G MacGrogan, A Avril, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2005
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapyR Arriagada, M G Lê, M Spielmann, et al.
Breast Cancer Research and Treatment|April 26, 2012
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicityM Toulmonde, N Madranges, V Brouste, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1988
Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trialJ Bonneterre, L Mauriac, B Weber, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/dayJ Bonneterre, H Coppens, L Mauriac, et al.
Chirurgie; Memoires De L'Academie De Chirurgie|September 30, 1998
[Results of 10 years of a randomized trial of neoadjuvant chemotherapy in breast cancers larger than 3 cm]A Avril, A Faucher, E Bussières, et al.
Pageof 9